Composition of matter patent for qn-302 granted by united states patent and trademark office

Carlsbad, calif., march 21, 2023 (globe newswire) -- qualigen therapeutics, inc. (“qualigen” or “the company,” nasdaq: qlgn), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for orphan drug designation, while also commercializing diagnostics, today announces the united states patent and trademarks office (uspto) has granted the company patent number 11,560,380 for qn-302, its lead oncology investigational drug candidate, a small molecule selective transcription inhibitor with strong binding affinity to g4 complexes prevalent in cancer cells being investigated for solid tumors, including pancreatic cancer.
QLGN Ratings Summary
QLGN Quant Ranking